Aclaris Therapeutics Doses First Patient In Phase 2a Trial Of ATI-2138 For Moderate To Severe Atopic Dermatitis
Portfolio Pulse from Benzinga Newsdesk
Aclaris Therapeutics has initiated a Phase 2a trial for ATI-2138, targeting moderate to severe atopic dermatitis. The trial will assess safety, tolerability, and efficacy over 12 weeks with 15 subjects in the US. Results are expected in the first half of 2025.
September 17, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aclaris Therapeutics has dosed the first patient in a Phase 2a trial for ATI-2138, focusing on moderate to severe atopic dermatitis. The trial will evaluate safety and efficacy over 12 weeks, with results expected in the first half of 2025.
The initiation of the Phase 2a trial is a positive development for Aclaris Therapeutics as it progresses its pipeline. Successful trial outcomes could enhance the company's product offerings and market position, potentially boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100